Clinical implementation of MRI-based organs-at-risk auto-segmentation with convolutional networks for prostate radiotherapy

Abstract Background: The aim of this study was to compare a commercial dosimetry workstation (PLANET®Dose) and the dosimetry approach (GE Dosimetry Toolkit® and OLINDA/EXM® V1.0) currently used in our department for quantification of the absorbed dose (AD) to organs at risk after peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE.Methods: An evaluation on phantom was performed to determine the SPECT calibration factor variations over time and to compare the Time Integrated Activity Coefficients (TIACs) obtained with the two approaches. Then, dosimetry was carried out with the two tools in 21 patients with neuroendocrine tumours after the first and second injection of 7.2 ± 0.2 GBq of [177Lu]Lu-DOTA-TATE (40 dosimetry analyses with each software). SPECT/CT images were acquired at 4h, 24h, 72h and 192h post-injection and were reconstructed using the Xeleris software (General Electric). The liver, spleen and kidneys masses and TIACs were determined using Dosimetry Toolkit® (DTK) and PLANET®Dose. The ADs were calculated using OLINDA/EXM® V1.0 and the Local Deposition Method (LDM) or Dose voxel-Kernel convolution (DK) on PLANET®Dose.Results: With the phantom, the 3D calibration factors showed a slight variation (0.8% and 3.3%) over time, and TIACs of 225.19h and 217.52h were obtained with DTK and PLANETâDose, respectively. In patients, the root mean square deviation value was 8.9% for the organ masses, 8.1% for the TIACs, and 9.1% and 7.8% for the ADs calculated with LDM and DK, respectively. The Lin’s concordance correlation coefficient was 0.99 and the Bland-Altman plot analysis estimated that the AD value difference between methods ranged from -0.75 Gy to 0.49 Gy, from -0.20 Gy to 0.64 Gy, and from -0.43 to 1.03 Gy for 95% of the 40 liver, kidneys and spleen dosimetry analyses. The dosimetry method had a minor influence on AD differences compared with the image registration and organ segmentation steps.Conclusions: The ADs to organs at risk obtained with the new workstation PLANET®Dose are concordant with those calculated with the currently used software and in agreement with the literature. These results validate the use of PLANET®Dose in clinical routine for patient dosimetry after targeted radiotherapy with [177Lu]Lu-DOTA-TATE.

Download Full-text

PO-0971: Segmentation of organs at risk using superpixels on MRI or CT images in prostate radiotherapy

Radiotherapy and Oncology ◽

10.1016/s0167-8140(15)40963-6 ◽

2015 ◽

Vol 115 ◽

pp. S515

Author(s):

M. Guinin ◽

S. Ruan ◽

L. Nkhali ◽

B. Dubray ◽

L. Massoptier ◽

...

Keyword(s):

At Risk ◽

Organs At Risk ◽

Ct Images ◽

Prostate Radiotherapy

Download Full-text

Clinical implementation of PLANET®Dose for dosimetric assessment after [177Lu]Lu-DOTA-TATE : comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.0

10.21203/rs.3.rs-36998/v2 ◽

2020 ◽

Author(s):

Lore Santoro ◽

Laurine Pitalot ◽

Dorian Trauchessec ◽

Erick Mora-Ramirez ◽

Pierre-Olivier Kotzki ◽

...

Keyword(s):

At Risk ◽

Organs At Risk ◽

Absorbed Dose ◽

Peptide Receptor Radionuclide Therapy ◽

Slight Variation ◽

Clinical Implementation ◽

Absorbed Doses ◽

Plot Analysis ◽

The Difference ◽

Over Time

Abstract Background: The aim of this study was to compare a commercial dosimetry workstation (PLANET®Dose) and the dosimetry approach (GE Dosimetry Toolkit® and OLINDA/EXM® V1.0) currently used in our department for quantification of the absorbed dose in organs at risk after peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE. Methods: An evaluation on phantom was performed to determine the SPECT calibration factor variations over time and to compare the Time Integrated Activity Coefficients (TIACs) and absorbed doses obtained with the two tools. Then, the two tools were used for dosimetry evaluation in 21 patients with neuroendocrine tumours after the first and second injection of 7.2 ± 0.2 GBq of [177Lu]Lu-DOTA-TATE (40 dosimetry analyses with each software). SPECT/CT images were acquired at 4h, 24h, 72h and 192h after [177Lu]Lu-DOTA-TATE injection and were reconstructed using the Xeleris software (General Electric). The liver, spleen and kidney masses, TIACs and absorbed doses were calculated using i) GE Dosimetry Toolkit® (DTK) and OLINDA/EXM® V1.0 and ii) the Local Deposition Method (LDM) or Dose voxel-Kernel convolution (DK) on PLANET®Dose. Results: With the phantom, the 3D calibration factors showed a slight variation (0.8% and 3.3%) over time and TIACs of 225.19h and 217.52h were obtained with DTK and PLANET®Dose, respectively. In patients, the root mean square deviation value was 8.9% for the organ masses, 8.1% for the TIACs, and 9.1 and 7.8% for the absorbed doses with LDM and DK, respectively. The Lin’s concordance correlation coefficient was 0.99 and the Bland-Altman plot analysis estimated that the difference of absorbed dose values between methods ranged from -0.75 Gy to 0.49 Gy, from -0.20 Gy to 0.64 Gy and from -0.43 to 1.03 Gy for approximately 95% of the 40 liver, kidneys and spleen dosimetry analyses. A difference of 2.2% was obtained between the absorbed doses to organs at risk calculated with LDM and DK. Conclusions: The absorbed doses to organs at risk obtained with the new workstation are concordant with those calculated with the currently used software and in agreement with the literature. These results validate the use of PLANET®Dose in clinical routine for patient dosimetry after targeted radiotherapy with [177Lu]Lu-DOTA-TATE.

Download Full-text

Clinical implementation of dose-volume histogram predictions for organs-at-risk in IMRT planning

Journal of Physics Conference Series ◽

10.1088/1742-6596/489/1/012055 ◽

2014 ◽

Vol 489 ◽

pp. 012055 ◽

Cited By ~ 7

Author(s):

K L Moore ◽

L M Appenzoller ◽

J Tan ◽

J M Michalski ◽

W L Thorstad ◽

...

Keyword(s):

At Risk ◽

Organs At Risk ◽

Dose Volume Histogram ◽

Clinical Implementation ◽

Dose Volume ◽

Imrt Planning

Download Full-text

Atlas Based Segmentation and Mapping of Organs at Risk from Planning CT for the Development of Voxel-Wise Predictive Models of Toxicity in Prostate Radiotherapy

Prostate Cancer Imaging. Computer-Aided Diagnosis, Prognosis, and Intervention - Lecture Notes in Computer Science ◽

10.1007/978-3-642-15989-3_6 ◽

2010 ◽

pp. 42-51 ◽

Cited By ~ 9

Author(s):

Oscar Acosta ◽

Jason Dowling ◽

Guillaume Cazoulat ◽

Antoine Simon ◽

Olivier Salvado ◽

...

Keyword(s):

At Risk ◽

Predictive Models ◽

Organs At Risk ◽

Prostate Radiotherapy ◽

Planning Ct

Download Full-text

Clinical implementation of PLANET® Dose for dosimetric assessment after [177Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.0

EJNMMI Research ◽

10.1186/s13550-020-00737-8 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Lore Santoro ◽

L. Pitalot ◽

D. Trauchessec ◽

E. Mora-Ramirez ◽

P. O. Kotzki ◽

...

Keyword(s):

At Risk ◽

Organs At Risk ◽

Absorbed Dose ◽

Peptide Receptor Radionuclide Therapy ◽

Slight Variation ◽

Clinical Implementation ◽

Plot Analysis ◽

A Minor ◽

Local Deposition ◽

Over Time

Abstract Background The aim of this study was to compare a commercial dosimetry workstation (PLANET® Dose) and the dosimetry approach (GE Dosimetry Toolkit® and OLINDA/EXM® V1.0) currently used in our department for quantification of the absorbed dose (AD) to organs at risk after peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE. Methods An evaluation on phantom was performed to determine the SPECT calibration factor variations over time and to compare the Time Integrated Activity Coefficients (TIACs) obtained with the two approaches. Then, dosimetry was carried out with the two tools in 21 patients with neuroendocrine tumours after the first and second injection of 7.2 ± 0.2 GBq of [177Lu]Lu-DOTA-TATE (40 dosimetry analyses with each software). SPECT/CT images were acquired at 4 h, 24 h, 72 h and 192 h post-injection and were reconstructed using the Xeleris software (General Electric). The liver, spleen and kidneys masses and TIACs were determined using Dosimetry Toolkit® (DTK) and PLANET® Dose. The ADs were calculated using OLINDA/EXM® V1.0 and the Local Deposition Method (LDM) or Dose voxel-Kernel convolution (DK) on PLANET® Dose. Results With the phantom, the 3D calibration factors showed a slight variation (0.8% and 3.3%) over time, and TIACs of 225.19 h and 217.52 h were obtained with DTK and PLANET® Dose, respectively. In patients, the root mean square deviation value was 8.9% for the organ masses, 8.1% for the TIACs, and 9.1% and 7.8% for the ADs calculated with LDM and DK, respectively. The Lin’s concordance correlation coefficient was 0.99 and the Bland–Altman plot analysis estimated that the AD value difference between methods ranged from − 0.75 to 0.49 Gy, from − 0.20 to 0.64 Gy, and from − 0.43 to 1.03 Gy for 95% of the 40 liver, kidneys and spleen dosimetry analyses. The dosimetry method had a minor influence on AD differences compared with the image registration and organ segmentation steps. Conclusions The ADs to organs at risk obtained with the new workstation PLANET® Dose are concordant with those calculated with the currently used software and in agreement with the literature. These results validate the use of PLANET® Dose in clinical routine for patient dosimetry after targeted radiotherapy with [177Lu]Lu-DOTA-TATE.

Download Full-text